Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) - Morschhauser, F; Flinn, IW; Advani, R (Lancet Haematol, 2019)